The authors showed that FGFR3, HRAS, and CDKN2B were more frequently mutated in UTUC than in bladder cancer, whereas TP53, RB1, and ARID1A were less frequently altered. This evidence concerns the gene RB1 and renal pelvis/ureter urothelial carcinoma.